Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats.
Br J Pharmacol
; 155(5): 722-30, 2008 Nov.
Article
de En
| MEDLINE
| ID: mdl-18776919
ABSTRACT
BACKGROUND AND PURPOSE:
VGX-1027 is a novel, low molecular weight, immunomodulatory compound that has shown efficacy against a variety of immuno-inflammatory disease models in animals including autoimmune diabetes in NOD mice, collagen-induced arthritis and chemically induced inflammatory colitis. Here, we have studied the effects of VGX-1027 on the development of endotoxin-induced uveitis (EIU) in male Lewis rats, as a model of inflammatory ocular diseases in humans. EXPERIMENTALAPPROACH:
EIU was induced by a single footpad injection of 200 microg lipopolysaccharide (LPS). Groups of rats were treated with either VGX-1027 (25 mg kg(-1)) or its vehicle at different time points (30 min, 6 h or 12 h) after the challenge with LPS or, as positive control, with dexamethasone. The rats were killed within 16 h after LPS challenge, and the eyes and aqueous humor were collected to study serological, immunological and histological signs of EIU. KEYRESULTS:
The rats treated with VGX-1027 within 6 h after LPS challenge exhibited milder clinical, histological and laboratory signs of EIU than those treated with vehicle. CONCLUSION AND IMPLICATIONS This study provides the first evidence that systemic treatment with VGX-1027 counteracts the uveitis-inducing effect of LPS in rats and suggests that this drug may have potential in the treatment of immuno-inflammatory conditions of the eye in humans.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Oxazoles
/
Uvéite
/
Lipopolysaccharides
/
Facteurs immunologiques
/
Acétates
Type d'étude:
Prognostic_studies
Limites:
Animals
Langue:
En
Journal:
Br J Pharmacol
Année:
2008
Type de document:
Article
Pays d'affiliation:
Italie